Last updated on June 2019

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Brief description of study

The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.

Detailed Study Description

This study has been designed as a Phase I, open-label, dose finding study with a dose escalation part and a dose expansion part in adult patients with selected advanced solid tumors. The study treatment, TNO155, will be taken until the patient experiences unacceptable toxicity, progressive disease and/or treatment is discontinued at the discretion of the investigator or the patient or due to withdrawal of consent. Some patients will be participating in a food effect investigation as an exploratory objective.

Clinical Study Identifier: NCT03114319

Find a site near you

Start Over

Novartis Investigative Site

Barcelona, Spain
  Connect »

Novartis Investigative Site

Hospitalet de LLobregat, Spain
  Connect »